Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 273 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pediatric Brain Tumor Clear all

Conditions: Brain Neoplasms, Glioma, Medulloblastoma
Interventions: RMP-7 and carboplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain and Central Nervous System Tumors, Pediatric Germ Cell Tumor, Extragonadal Germ Cell Tumor
Interventions: cisplatin, etoposide, conventional surgery, neoadjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 3 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2005
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Lymphoma, Childhood Lymphoma, Solid Tumor, Childhood Solid Tumor, Neuroblastoma, Ewing Sarcoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Medulloblastoma, Germ Cell Tumor, Wilms Tumor, Brain Neoplasms, Medulloblastoma, Childhood, Neuroectodermal Tumors, Primitive
Interventions: Genistein, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 1 Year to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Pediatric ALL, Concussion, Mild, Concussion, Brain, Concussion, Intermediate
Interventions: Active Rehabilitation Group/Case; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 8 Years to 18 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Recurrent Brain Tumor, Childhood, Ketogenic Diet
Interventions: Strict Classic Ketogenic Diet; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: filgrastim, carboplatin, etoposide, isotretinoin, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 20 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 52
States / cities: Little Rock, Arkansas • Oakland, California • Sacramento, California + 45 more

Conditions: Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: valproic acid; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 2 Years to 21 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 15
States / cities: Orange, California • Stanford, California • Washington D.C., District of Columbia + 12 more

Conditions: Brain Tumors, Solid Tumor
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 138 participants
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Cancer
Interventions: cyproheptadine hydrochloride, placebo; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 2 Years to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 14
States / cities: Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more

Conditions: Brain Tumors
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 18 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pediatric Brain Tumor, Pediatric Spine Tumor
Interventions: pNANO Assessment; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 1 Year to 17 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Leukemia, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: ixabepilone; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Pediatric Brain Tumors
Interventions: FET PET/MRI; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 6 Years to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Brain and Central Nervous System Tumors
Interventions: GDC-0084, radiation therapy; Drug · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Brain Neoplasms, Neuroblastoma
Interventions: phenylbutyrate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor, Central Nervous System Tumor, Pediatric Cancer, Adult Cancer Patients, CNS Tumor, Childhood, CNS Tumor, Adult, Brainstem Glioma, Diffuse Midline Glioma, DMG
Interventions: BCB-276; Biological
Lead sponsor: BrainChild Bio, Inc; Industry
Eligibility: 1 Year to 26 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 3 more

Conditions: Malignant Glioma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma, Atypical Teratoid/Rhabdoid Tumor of Brain, Medulloblastoma, Ependymoma, Pleomorphic Xanthoastrocytoma of Brain, Embryonal Tumor of Brain
Interventions: Polio/Rhinovirus Recombinant (PVSRIPO); Biological
Lead sponsor: Istari Oncology, Inc.; Industry
Eligibility: 12 Years to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma
Interventions: Palbociclib, Temozolomide, Irinotecan, Topotecan, Cyclophosphamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 20 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more

Conditions: Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Chronic Myelogenous Leukemia, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Spinal Cord Neoplasm, Childhood Supratentorial Ependymoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Refractory Chronic Lymphocytic Leukemia, Relapsing Chronic Myelogenous Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: romidepsin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: liposomal cytarabine; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 1 Year to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 5
States / cities: Los Angeles, California • Stanford, California • Dallas, Texas + 2 more

Conditions: Diffuse Intrinsic Pontine Glioma, PNET, Ependymoma, Germinoma, Medulloblastoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Month to 21 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain Tumor
Interventions: Bright Light Exposure, Dim Light Exposure, Cognitive Assessment; Behavioral · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
Interventions: GWP42003-P; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 1 Month to 23 Months
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more

Conditions: Tethered Spinal Cord, Brain Tumor, Cranio Cervical Compression
Interventions: Isoflurane, Propofol, Dexmedetomidine; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 2 Years to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors

Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

Concussion Active Rehabilitation

Strict Classic Ketogenic Diet as a Therapy for Recurrent or Progressive and Refractory Brain Tumors in Children

High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas

Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors

Understanding Communication in Healthcare to Achieve Trust (U-CHAT)

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

Arterial Spin Labeling Perfusion Magnetic Resonance (MR) Imaging in Pediatric Brain Tumors

Evaluation of the Neurologic Assessment in Pediatric Neuro-Oncology (pNANO)

Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy

FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors

Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas

Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy

Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia

Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors

Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

Systematic Light Exposure in Pediatric Brain Tumor Survivors

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

Dexmedetomidine on Intraoperative Somatosensory and Motor Evoked Potential Monitoring During Neurosurgery in Pediatric Patients